ProKidney (PROK) to Release Quarterly Earnings on Monday

ProKidney (NASDAQ:PROK) will likely be announcing its Q4 2025 results before the market opens on Monday, March 16th. Analysts expect ProKidney to post earnings of ($0.16) per share and revenue of $0.0010 million for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Tuesday, March 17, 2026 at 12:30 PM ET.

ProKidney Stock Performance

Shares of PROK opened at $2.25 on Friday. ProKidney has a fifty-two week low of $0.46 and a fifty-two week high of $7.13. The company has a market capitalization of $676.87 million, a PE ratio of -4.09 and a beta of 1.75. The stock has a fifty day moving average of $2.18 and a two-hundred day moving average of $2.44.

Analysts Set New Price Targets

PROK has been the subject of a number of recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ProKidney in a research report on Thursday, January 22nd. HC Wainwright initiated coverage on ProKidney in a research note on Tuesday, December 16th. They issued a “buy” rating and a $12.00 price target on the stock. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $7.40.

Hedge Funds Weigh In On ProKidney

A number of hedge funds have recently made changes to their positions in the stock. Millennium Management LLC acquired a new stake in shares of ProKidney during the 3rd quarter worth $4,734,000. JPMorgan Chase & Co. boosted its holdings in ProKidney by 3,024.9% in the second quarter. JPMorgan Chase & Co. now owns 1,668,642 shares of the company’s stock valued at $988,000 after acquiring an additional 1,615,243 shares during the last quarter. Geode Capital Management LLC boosted its holdings in ProKidney by 9.2% in the fourth quarter. Geode Capital Management LLC now owns 1,197,530 shares of the company’s stock valued at $2,684,000 after acquiring an additional 100,748 shares during the last quarter. Renaissance Technologies LLC grew its position in ProKidney by 578.6% during the fourth quarter. Renaissance Technologies LLC now owns 895,705 shares of the company’s stock valued at $2,006,000 after acquiring an additional 763,705 shares during the period. Finally, Bank of America Corp DE grew its position in ProKidney by 12.4% during the second quarter. Bank of America Corp DE now owns 846,154 shares of the company’s stock valued at $501,000 after acquiring an additional 93,322 shares during the period. Institutional investors and hedge funds own 51.59% of the company’s stock.

About ProKidney

ProKidney, Inc (NASDAQ: PROK) is a clinical-stage biotechnology company focused on developing cell-based therapies for kidney diseases. The company’s research and development activities center on harnessing human-derived proximal tubule cells to address conditions such as acute kidney injury (AKI) and chronic kidney disease (CKD). By targeting the underlying cellular mechanisms of renal injury and dysfunction, ProKidney aims to offer novel regenerative medicine approaches that go beyond current supportive care options.

ProKidney’s lead programs utilize proprietary methods for isolating and expanding renal epithelial cells to create injectable therapeutic products.